Amendments to the Claims

Please amend the listing of claims as follows:

1. (Original) A compound of structural formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein

Ar is:

aryl or heteroaryl which may both be substituted or unsubstituted;

R_1 is independently:

hydrogen,

hydroxy,

cyano,

nitro,

halo,

alkyl,

alkoxy or

haloalkyl;

R_2 is:



each R_3 is independently:

hydrogen,

halo,

alkyl,

haloalkyl,

hydroxy,

alkoxy,

S-alkyl,

SO_2-alkyl,

O-alkenyl,

S-alkenyl,

$NR_7C(O)R_7$,

$NR_7SO_2R_7$,

$N(R_7)_2$

(D)-cycloalkyl,

(D)-aryl,

(D)-heteroaryl or

(D)-heterocyclyl (wherein heterocyclyl excludes a heterocyclyl containing a single nitrogen), and

wherein aryl, heteroaryl, heterocyclyl, alkyl and/or cycloalkyl may be substituted or unsubstituted, and two adjacent R_3 may form a 4- to 7-membered ring;

R_7 and R_8 are each independently:

hydrogen,

alkyl or

cycloalkyl, or

R_7 and R_8 together with the nitrogen to which they are attached form a 5- to 8-membered ring,

wherein alkyl and cycloalkyl are both unsubstituted or substituted;

D is a bond or alkyl;

X is CH or N;

Y is O or NR_7;

n is 1 - 4;

m is 0 - 3;

o is 0 - 2;

p is 0 - 2;

q is 1 or 2;

s is 0 - 4.

2. (Original) The compound of claim 1, wherein

Ar is:

aryl which may be substituted with one to three substituents independently selected from the group consisting of cyano, nitro, perfluoroalkoxy, halo, alkyl, (D)-cycloalkyl, alkoxy and/or haloalkyl;

R_1 is independently:

hydrogen,

hydroxy,

halo,

alkyl,

alkoxy or

haloalkyl;

R_2 is:





each R_3 is independently:

hydrogen,

halo,

alkyl,

haloalkyl,

hydroxy,

alkoxy,

S-alkyl or

SO_2-alkyl,
O-alkenyl or
S-alkenyl;

R_7 and R_8 are each independently:
hydrogen,
alkyl or
cycloalkyl, or
R_7 and R_8 together with the nitrogen to which they are attached form a 5- to 7-membered ring optionally containing an additional heteroatom selected from O, S and NR_4;

D is a bond or CH_2;
X is CH or N;
Y is NR_7 or O;
n is 1 or 2;
m is 1 - 3;
o is 0 or 1;
p is 0 or 1;
q is 1;
s is 1 - 3.

3. (Currently Amended) The compound of claim 1 ~~or 2~~, wherein
Ar is:
phenyl or naphthyl which may be substituted with one or two substituents independently selected from the group consisting of perfluoroalkoxy, halo, alkyl, alkoxy and haloalkyl;

R_1 is independently:
hydrogen,
alkoxy,
halo or
alkyl;

R_2 is:




each R_3 is independently:

hydrogen,

hydroxy,

alkoxy,

SO_2-alkyl or

iso-propyl;

R_7 and R_8 are each independently:

hydrogen or

alkyl, or

R_7 and R_8 together with the nitrogen to which they are attached form a 6-membered ring optionally containing an additional oxygen atom;

X is CH or N;

Y is N-alkyl or O;

n is 1;

m is 1 - 3;

o is 0 or 1;

p is 0 or 1;

q is 1.

4. (Currently Amended) The compound of ~~any of claims 1 to 3~~claim 1, wherein Ar is:

phenyl or naphthyl which may be substituted with halo;

R_1 is hydrogen;

R_2 is:




each R_3 is independently:

hydrogen,

hydroxy,

alkoxy,

SO_2-alkyl or

iso-propyl;

R_7 and R_8 are each independently:

hydrogen or

alkyl, or

R_7 and R_8 together with the nitrogen to which they are attached form a 5- to 6-membered ring optionally containing an additional oxygen atom;

X is CH or N;

n is 1;

m is 1 or 2;

o is 0;

p is 0;

q is 1

s is 1 - 2.

5. (Currently Amended) ~~The compound of any of claims 1 to 4 for use as a~~ A medicament comprising the compound of claim 1.

6. (Currently Amended) ~~Use of the compound of any of claims 1 to 4 for the preparation of a medicament for the treatment or prevention of~~ A method of treating or preventing disorders, diseases or conditions responsive to the modulation of the melanocortin-4 receptor in a mammal, where modulation means activation in the case of MC4-R agonists or inactivation in the case of MC4-R antagonists, the method comprising administering to a human or mammal an effective amount of the compound of claim 1.

7. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of cancer cachexia.~~ A method of treating or preventing cancer cachexia, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

8. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of muscle wasting.~~ A method of treating or preventing muscle wasting, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

9. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of anorexia.~~ A method of treating or preventing anorexia, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

10. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of anxiety and/or depression.~~ A method of treating or preventing anxiety and/or depression, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

11. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of obesity.~~ A method of treating or preventing obesity, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

12. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of diabetes mellitus.~~ A method of treating or preventing diabetes mellitus, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

13. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of male or female sexual dysfunction.~~ A method of treating or preventing male or female sexual dysfunction, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

14. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of erectile dysfunction.~~ A method of treating or preventing erectile dysfunction, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

15. (Currently Amended) A pharmaceutical composition which comprises a compound of ~~any of claims 1 to 4~~claim 1 and a pharmaceutically acceptable carrier.